NCI-H69/CPR

96042328, human lung, Not specified

• 分類程式碼代碼: 41106514

属性

• product name: NCI-H69/CPR, 96042328
• 生物源: human lung
• 增長模式: Aggregates in suspension
• 染色體組型: Not specified
• 形態學: Not specified
• 產品: Not specified
• 受體: Not specified
• 技術: cell culture | mammalian: suitable
• 相關疾病: cancer
• 運輸包裝: dry ice
• 儲存溫度: −196°C

说明

細胞系來源

Human small cell lung cancer, drug-resistant

細胞系描述

NCI-H69/CPR is a drug resistant subline of NCI-H69 (Sigma Catalogue number. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.

應用

Drug-resistance studies, small cell lung cancer

培養基

RPMI 1640 + 2mM Glutamine + 0.4μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).

例行更新培養

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37ºC; resuscitate in drug-free medium until first passage.

其他說明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.